Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase IIa-IIb study of low-dose memantine as long-term supportive therapy in symptomatic sickle cell disease
MOH_2017-11-22_001900Phase 2Not yet recruiting
- Sponsor
- פרופ' אריאל קורן
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of memantine, sponsored by פרופ' אריאל קורן. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
memantine
Beyond the preview
Go deeper on MOH_2017-11-22_001900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-22_001900.